BRAIN Biotech AG
XETRA:BNN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
BRAIN Biotech AG
Cash from Operating Activities
BRAIN Biotech AG
Cash from Operating Activities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash from Operating Activities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
BRAIN Biotech AG
XETRA:BNN
|
Cash from Operating Activities
-€8m
|
CAGR 3-Years
-34%
|
CAGR 5-Years
0%
|
CAGR 10-Years
-20%
|
|
|
Wacker Chemie AG
XETRA:WCH
|
Cash from Operating Activities
€542.6m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-9%
|
CAGR 10-Years
-1%
|
|
|
Evonik Industries AG
XETRA:EVK
|
Cash from Operating Activities
€1.4B
|
CAGR 3-Years
-4%
|
CAGR 5-Years
-4%
|
CAGR 10-Years
-3%
|
|
|
Covestro AG
XETRA:1COV
|
Cash from Operating Activities
€798m
|
CAGR 3-Years
1%
|
CAGR 5-Years
-8%
|
CAGR 10-Years
-5%
|
|
|
AlzChem Group AG
XETRA:ACT
|
Cash from Operating Activities
€137m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
23%
|
CAGR 10-Years
N/A
|
|
|
Symrise AG
XETRA:SY1
|
Cash from Operating Activities
€769m
|
CAGR 3-Years
30%
|
CAGR 5-Years
4%
|
CAGR 10-Years
8%
|
|
BRAIN Biotech AG
Glance View
BRAIN Biotech AG is a technology company, which engages in the development and commercialization of bioactives, natural compounds, and proprietary enzymes. The company is headquartered in Zwingenberg, Hessen and currently employs 293 full-time employees. The company went IPO on 2016-02-09. Research & Development activities focus on bioactive natural compounds, tailored enzymes and high-performance microorganisms.
See Also
What is BRAIN Biotech AG's Cash from Operating Activities?
Cash from Operating Activities
-8m
EUR
Based on the financial report for Dec 31, 2025, BRAIN Biotech AG's Cash from Operating Activities amounts to -8m EUR.
What is BRAIN Biotech AG's Cash from Operating Activities growth rate?
Cash from Operating Activities CAGR 10Y
-20%
Over the last year, the Cash from Operating Activities growth was -86%. The average annual Cash from Operating Activities growth rates for BRAIN Biotech AG have been -34% over the past three years , and -20% over the past ten years .
